AAAAAA

   
Results: 1-9 |
Results: 9
CLINICAL AND IMMUNOLOGICAL EFFECTS OF A PRIMATIZED(R) ANTI-CD4 MONOCLONAL-ANTIBODY IN ACTIVE RHEUMATOID-ARTHRITIS - RESULTS OF A PHASE-I, SINGLE-DOSE, DOSE ESCALATING TRIAL
Authors: YOCUM DE SOLINGER AM TESSER J GLUCK O CORNETT M OSULLIVAN F NORDENSSON K DALLAIRE B SHEN CD LIPANI J
Citation: De. Yocum et al., CLINICAL AND IMMUNOLOGICAL EFFECTS OF A PRIMATIZED(R) ANTI-CD4 MONOCLONAL-ANTIBODY IN ACTIVE RHEUMATOID-ARTHRITIS - RESULTS OF A PHASE-I, SINGLE-DOSE, DOSE ESCALATING TRIAL, Journal of rheumatology, 25(7), 1998, pp. 1257-1262
A DOUBLE-MASKED COMPARISON OF NAPRELAN(R) AND NABUMETONE IN OSTEOARTHRITIS OF THE KNEE
Authors: FLEISCHMANN RM FLINT K CONSTANTINE G KOLECKI B ADELIZZI R BARAF HSB BOCKOW B CLARK G DALGIN P GLUCK O HAMM D HARRIS ER KATZ P KILPATRICK F
Citation: Rm. Fleischmann et al., A DOUBLE-MASKED COMPARISON OF NAPRELAN(R) AND NABUMETONE IN OSTEOARTHRITIS OF THE KNEE, Clinical therapeutics, 19(4), 1997, pp. 642-655
RESULTS OF AN OPEN-LABEL, DOSE-RANGING, SAFETY AND PHARMACOKINETIC TRIAL OF THE HUMANIZED TUMOR-NECROSIS-FACTOR ANTIBODY (HTA), BAY-103356,IN PATIENTS WITH ACTIVE RHEUMATOID-ARTHRITIS (RA)
Authors: EVANS J YOCUM DE MARICIC M GLUCK O TESSER J CHEN Z BAYLINK DJ FLETCHER MP
Citation: J. Evans et al., RESULTS OF AN OPEN-LABEL, DOSE-RANGING, SAFETY AND PHARMACOKINETIC TRIAL OF THE HUMANIZED TUMOR-NECROSIS-FACTOR ANTIBODY (HTA), BAY-103356,IN PATIENTS WITH ACTIVE RHEUMATOID-ARTHRITIS (RA), Arthritis and rheumatism, 40(9), 1997, pp. 1158-1158
COMBINATION TREATMENT OF SEVERE RHEUMATOID-ARTHRITIS WITH CYCLOSPORINE AND METHOTREXATE FOR 48 WEEKS - AN OPEN-LABEL EXTENSION STUDY
Authors: STEIN CM PINCUS T YOCUM D TUGWELL P WELLS G GLUCK O KRAAG G TORLEY H TESSER J MCKENDRY R BROOKS RH
Citation: Cm. Stein et al., COMBINATION TREATMENT OF SEVERE RHEUMATOID-ARTHRITIS WITH CYCLOSPORINE AND METHOTREXATE FOR 48 WEEKS - AN OPEN-LABEL EXTENSION STUDY, Arthritis and rheumatism, 40(10), 1997, pp. 1843-1851
RARE-EARTH ION SIZE EFFECT ON RESISTIVITY, SUSCEPTIBILITY, AND SUPERCONDUCTIVITY OF RBA(2)CU(3-X)ZN(X)O(7-Y) (R=YB, ER, Y, DY, GD, EU, SM, AND ND)
Authors: XU Y ATAALLAH SS BERGER MG GLUCK O
Citation: Y. Xu et al., RARE-EARTH ION SIZE EFFECT ON RESISTIVITY, SUSCEPTIBILITY, AND SUPERCONDUCTIVITY OF RBA(2)CU(3-X)ZN(X)O(7-Y) (R=YB, ER, Y, DY, GD, EU, SM, AND ND), Physical review. B, Condensed matter, 53(22), 1996, pp. 15245-15253
ILLUMINATION-ASSISTED FORMATION OF POROUS SILICON
Authors: THONISSEN M BERGER MG ARENSFISCHER R GLUCK O KRUGER M LUTH H
Citation: M. Thonissen et al., ILLUMINATION-ASSISTED FORMATION OF POROUS SILICON, Thin solid films, 276(1-2), 1996, pp. 21-24
THE INFLUENCE OF THE DOPING LEVEL ON THE OPTICAL-PROPERTIES OF POROUSSILICON
Authors: HILBRICH S THEISS W ARENSFISCHER R GLUCK O BERGER MG
Citation: S. Hilbrich et al., THE INFLUENCE OF THE DOPING LEVEL ON THE OPTICAL-PROPERTIES OF POROUSSILICON, Thin solid films, 276(1-2), 1996, pp. 231-234
SILICONE BREAST IMPLANT - ASSOCIATED MUSCULOSKELETAL MANIFESTATIONS
Authors: CUELLAR ML GLUCK O MOLINA JF GUTIERREZ S GARCIA C ESPINOZA R
Citation: Ml. Cuellar et al., SILICONE BREAST IMPLANT - ASSOCIATED MUSCULOSKELETAL MANIFESTATIONS, Clinical rheumatology, 14(6), 1995, pp. 667-672
COMBINATION THERAPY WITH CYCLOSPORINE AND METHOTREXATE IN SEVERE RHEUMATOID-ARTHRITIS
Authors: TUGWELL P PINCUS T YOCUM D STEIN M GLUCK O KRAAG G MCKENDRY R TESSER J BAKER P WELLS G
Citation: P. Tugwell et al., COMBINATION THERAPY WITH CYCLOSPORINE AND METHOTREXATE IN SEVERE RHEUMATOID-ARTHRITIS, The New England journal of medicine, 333(3), 1995, pp. 137-141
Risultati: 1-9 |